nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—ABCB1—Mitomycin—urinary bladder cancer	0.0838	0.128	CbGbCtD
Vismodegib—ABCG2—Fluorouracil—urinary bladder cancer	0.0572	0.0877	CbGbCtD
Vismodegib—ABCG2—Carboplatin—urinary bladder cancer	0.0569	0.0872	CbGbCtD
Vismodegib—ABCG2—Cisplatin—urinary bladder cancer	0.0486	0.0745	CbGbCtD
Vismodegib—ABCG2—Etoposide—urinary bladder cancer	0.0478	0.0732	CbGbCtD
Vismodegib—ALB—Fluorouracil—urinary bladder cancer	0.0395	0.0605	CbGbCtD
Vismodegib—CYP3A4—Thiotepa—urinary bladder cancer	0.0381	0.0583	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—urinary bladder cancer	0.0326	0.0499	CbGbCtD
Vismodegib—ABCG2—Methotrexate—urinary bladder cancer	0.0316	0.0484	CbGbCtD
Vismodegib—CYP2C8—Fluorouracil—urinary bladder cancer	0.0305	0.0467	CbGbCtD
Vismodegib—CYP2C8—Etoposide—urinary bladder cancer	0.0254	0.039	CbGbCtD
Vismodegib—ABCB1—Gemcitabine—urinary bladder cancer	0.0241	0.037	CbGbCtD
Vismodegib—ALB—Methotrexate—urinary bladder cancer	0.0218	0.0333	CbGbCtD
Vismodegib—CYP2C9—Fluorouracil—urinary bladder cancer	0.0213	0.0326	CbGbCtD
Vismodegib—CYP2C9—Cisplatin—urinary bladder cancer	0.0181	0.0277	CbGbCtD
Vismodegib—ABCB1—Cisplatin—urinary bladder cancer	0.0175	0.0269	CbGbCtD
Vismodegib—ABCB1—Etoposide—urinary bladder cancer	0.0172	0.0264	CbGbCtD
Vismodegib—ABCB1—Doxorubicin—urinary bladder cancer	0.0117	0.018	CbGbCtD
Vismodegib—ABCB1—Methotrexate—urinary bladder cancer	0.0114	0.0174	CbGbCtD
Vismodegib—CYP3A4—Etoposide—urinary bladder cancer	0.0103	0.0158	CbGbCtD
Vismodegib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00704	0.0108	CbGbCtD
Vismodegib—SHH—epithelium—urinary bladder cancer	0.00642	0.0863	CbGeAlD
Vismodegib—SMO—prostate gland—urinary bladder cancer	0.00611	0.0821	CbGeAlD
Vismodegib—SHH—renal system—urinary bladder cancer	0.00595	0.08	CbGeAlD
Vismodegib—CYP2C19—urine—urinary bladder cancer	0.00525	0.0706	CbGeAlD
Vismodegib—SMO—seminal vesicle—urinary bladder cancer	0.00517	0.0695	CbGeAlD
Vismodegib—SHH—female reproductive system—urinary bladder cancer	0.00477	0.0641	CbGeAlD
Vismodegib—SMO—urethra—urinary bladder cancer	0.00409	0.055	CbGeAlD
Vismodegib—CYP2C9—urine—urinary bladder cancer	0.00407	0.0547	CbGeAlD
Vismodegib—SMO—female reproductive system—urinary bladder cancer	0.00333	0.0448	CbGeAlD
Vismodegib—CYP3A4—urine—urinary bladder cancer	0.0031	0.0417	CbGeAlD
Vismodegib—SMO—vagina—urinary bladder cancer	0.00302	0.0405	CbGeAlD
Vismodegib—ORM1—prostate gland—urinary bladder cancer	0.00267	0.0359	CbGeAlD
Vismodegib—SMO—lymph node—urinary bladder cancer	0.00195	0.0262	CbGeAlD
Vismodegib—ABCG2—prostate gland—urinary bladder cancer	0.0016	0.0215	CbGeAlD
Vismodegib—Sulfasalazine—PPARG—urinary bladder cancer	0.00157	0.468	CrCbGaD
Vismodegib—ORM1—female reproductive system—urinary bladder cancer	0.00146	0.0196	CbGeAlD
Vismodegib—ABCG2—seminal vesicle—urinary bladder cancer	0.00135	0.0182	CbGeAlD
Vismodegib—Neoplasm malignant—Gemcitabine—urinary bladder cancer	0.00135	0.0107	CcSEcCtD
Vismodegib—Ageusia—Cisplatin—urinary bladder cancer	0.00133	0.0105	CcSEcCtD
Vismodegib—Musculoskeletal chest pain—Doxorubicin—urinary bladder cancer	0.00132	0.0105	CcSEcCtD
Vismodegib—Blood urea increased—Thiotepa—urinary bladder cancer	0.0013	0.0103	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00129	0.0102	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Gemcitabine—urinary bladder cancer	0.00122	0.00968	CcSEcCtD
Vismodegib—Alopecia—Mitomycin—urinary bladder cancer	0.00121	0.00961	CcSEcCtD
Vismodegib—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00116	0.00917	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Gemcitabine—urinary bladder cancer	0.00115	0.00916	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Thiotepa—urinary bladder cancer	0.00115	0.00908	CcSEcCtD
Vismodegib—Etoricoxib—PTGS2—urinary bladder cancer	0.00113	0.335	CrCbGaD
Vismodegib—CYP2C8—renal system—urinary bladder cancer	0.00112	0.0151	CbGeAlD
Vismodegib—Pain—Carboplatin—urinary bladder cancer	0.00112	0.00888	CcSEcCtD
Vismodegib—Abdominal pain—Valrubicin—urinary bladder cancer	0.00112	0.00886	CcSEcCtD
Vismodegib—Azotaemia—Methotrexate—urinary bladder cancer	0.00111	0.00879	CcSEcCtD
Vismodegib—Blood urea increased—Gemcitabine—urinary bladder cancer	0.00109	0.00865	CcSEcCtD
Vismodegib—ABCG2—urethra—urinary bladder cancer	0.00107	0.0144	CbGeAlD
Vismodegib—Asthenia—Valrubicin—urinary bladder cancer	0.00101	0.00804	CcSEcCtD
Vismodegib—Pruritus—Valrubicin—urinary bladder cancer	0.001	0.00793	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Etoposide—urinary bladder cancer	0.000986	0.00782	CcSEcCtD
Vismodegib—Diarrhoea—Valrubicin—urinary bladder cancer	0.000967	0.00767	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Gemcitabine—urinary bladder cancer	0.000963	0.00764	CcSEcCtD
Vismodegib—CYP2C19—vagina—urinary bladder cancer	0.00093	0.0125	CbGeAlD
Vismodegib—Dehydration—Thiotepa—urinary bladder cancer	0.000926	0.00735	CcSEcCtD
Vismodegib—Vomiting—Valrubicin—urinary bladder cancer	0.000898	0.00713	CcSEcCtD
Vismodegib—CYP2C8—female reproductive system—urinary bladder cancer	0.000898	0.0121	CbGeAlD
Vismodegib—Aspartate aminotransferase increased—Thiotepa—urinary bladder cancer	0.000897	0.00712	CcSEcCtD
Vismodegib—Rash—Valrubicin—urinary bladder cancer	0.000891	0.00707	CcSEcCtD
Vismodegib—Dermatitis—Valrubicin—urinary bladder cancer	0.00089	0.00706	CcSEcCtD
Vismodegib—ORM1—lymph node—urinary bladder cancer	0.000852	0.0115	CbGeAlD
Vismodegib—Decreased appetite—Mitomycin—urinary bladder cancer	0.000846	0.00671	CcSEcCtD
Vismodegib—Nausea—Valrubicin—urinary bladder cancer	0.000839	0.00666	CcSEcCtD
Vismodegib—Fatigue—Mitomycin—urinary bladder cancer	0.000839	0.00666	CcSEcCtD
Vismodegib—Pain—Mitomycin—urinary bladder cancer	0.000832	0.0066	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Etoposide—urinary bladder cancer	0.000823	0.00653	CcSEcCtD
Vismodegib—CYP2C8—vagina—urinary bladder cancer	0.000812	0.0109	CbGeAlD
Vismodegib—CYP2C9—female reproductive system—urinary bladder cancer	0.000798	0.0107	CbGeAlD
Vismodegib—ABCG2—vagina—urinary bladder cancer	0.00079	0.0106	CbGeAlD
Vismodegib—ABCB1—prostate gland—urinary bladder cancer	0.000789	0.0106	CbGeAlD
Vismodegib—Hyponatraemia—Cisplatin—urinary bladder cancer	0.000784	0.00622	CcSEcCtD
Vismodegib—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.000763	0.00605	CcSEcCtD
Vismodegib—CYP3A4—renal system—urinary bladder cancer	0.000759	0.0102	CbGeAlD
Vismodegib—Aspartate aminotransferase increased—Gemcitabine—urinary bladder cancer	0.000755	0.00599	CcSEcCtD
Vismodegib—ALB—lymph node—urinary bladder cancer	0.000747	0.01	CbGeAlD
Vismodegib—Dehydration—Cisplatin—urinary bladder cancer	0.000726	0.00576	CcSEcCtD
Vismodegib—Hypokalaemia—Cisplatin—urinary bladder cancer	0.000711	0.00564	CcSEcCtD
Vismodegib—Breast disorder—Cisplatin—urinary bladder cancer	0.000706	0.0056	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Cisplatin—urinary bladder cancer	0.000703	0.00558	CcSEcCtD
Vismodegib—Asthenia—Mitomycin—urinary bladder cancer	0.000698	0.00554	CcSEcCtD
Vismodegib—Ageusia—Epirubicin—urinary bladder cancer	0.000682	0.00541	CcSEcCtD
Vismodegib—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.000677	0.00537	CcSEcCtD
Vismodegib—ABCB1—seminal vesicle—urinary bladder cancer	0.000667	0.00897	CbGeAlD
Vismodegib—Diarrhoea—Mitomycin—urinary bladder cancer	0.000666	0.00528	CcSEcCtD
Vismodegib—Sulfasalazine—PTGS2—urinary bladder cancer	0.000665	0.197	CrCbGaD
Vismodegib—Neoplasm malignant—Epirubicin—urinary bladder cancer	0.000647	0.00513	CcSEcCtD
Vismodegib—Ageusia—Doxorubicin—urinary bladder cancer	0.000631	0.00501	CcSEcCtD
Vismodegib—Amenorrhoea—Epirubicin—urinary bladder cancer	0.000629	0.00499	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Methotrexate—urinary bladder cancer	0.000624	0.00495	CcSEcCtD
Vismodegib—Vomiting—Mitomycin—urinary bladder cancer	0.000619	0.00491	CcSEcCtD
Vismodegib—Rash—Mitomycin—urinary bladder cancer	0.000614	0.00487	CcSEcCtD
Vismodegib—Dermatitis—Mitomycin—urinary bladder cancer	0.000613	0.00486	CcSEcCtD
Vismodegib—Alopecia—Thiotepa—urinary bladder cancer	0.000609	0.00483	CcSEcCtD
Vismodegib—CYP3A4—female reproductive system—urinary bladder cancer	0.000608	0.00818	CbGeAlD
Vismodegib—Malnutrition—Thiotepa—urinary bladder cancer	0.0006	0.00476	CcSEcCtD
Vismodegib—Neoplasm malignant—Doxorubicin—urinary bladder cancer	0.000599	0.00475	CcSEcCtD
Vismodegib—Amenorrhoea—Doxorubicin—urinary bladder cancer	0.000582	0.00462	CcSEcCtD
Vismodegib—Back pain—Thiotepa—urinary bladder cancer	0.00058	0.0046	CcSEcCtD
Vismodegib—ABCB1—epithelium—urinary bladder cancer	0.00058	0.00779	CbGeAlD
Vismodegib—Nausea—Mitomycin—urinary bladder cancer	0.000578	0.00459	CcSEcCtD
Vismodegib—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00057	0.00452	CcSEcCtD
Vismodegib—Musculoskeletal pain—Epirubicin—urinary bladder cancer	0.000559	0.00444	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Epirubicin—urinary bladder cancer	0.000553	0.00438	CcSEcCtD
Vismodegib—ABCB1—renal system—urinary bladder cancer	0.000538	0.00723	CbGeAlD
Vismodegib—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000531	0.00421	CcSEcCtD
Vismodegib—ABCB1—urethra—urinary bladder cancer	0.000528	0.0071	CbGeAlD
Vismodegib—Blood urea increased—Epirubicin—urinary bladder cancer	0.000522	0.00414	CcSEcCtD
Vismodegib—Musculoskeletal pain—Doxorubicin—urinary bladder cancer	0.000517	0.0041	CcSEcCtD
Vismodegib—Alopecia—Gemcitabine—urinary bladder cancer	0.000512	0.00406	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Doxorubicin—urinary bladder cancer	0.000511	0.00406	CcSEcCtD
Vismodegib—Myalgia—Thiotepa—urinary bladder cancer	0.000511	0.00405	CcSEcCtD
Vismodegib—Arthralgia—Thiotepa—urinary bladder cancer	0.000511	0.00405	CcSEcCtD
Vismodegib—ABCG2—lymph node—urinary bladder cancer	0.000511	0.00687	CbGeAlD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000507	0.00402	CcSEcCtD
Vismodegib—Alopecia—Fluorouracil—urinary bladder cancer	0.000504	0.004	CcSEcCtD
Vismodegib—Back pain—Gemcitabine—urinary bladder cancer	0.000488	0.00387	CcSEcCtD
Vismodegib—Blood urea increased—Doxorubicin—urinary bladder cancer	0.000483	0.00383	CcSEcCtD
Vismodegib—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00048	0.00381	CcSEcCtD
Vismodegib—Alopecia—Cisplatin—urinary bladder cancer	0.000477	0.00379	CcSEcCtD
Vismodegib—Skin disorder—Thiotepa—urinary bladder cancer	0.000476	0.00377	CcSEcCtD
Vismodegib—Malnutrition—Cisplatin—urinary bladder cancer	0.00047	0.00373	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Epirubicin—urinary bladder cancer	0.000461	0.00366	CcSEcCtD
Vismodegib—Muscle spasms—Cisplatin—urinary bladder cancer	0.000452	0.00359	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000446	0.00354	CcSEcCtD
Vismodegib—Alopecia—Etoposide—urinary bladder cancer	0.000437	0.00347	CcSEcCtD
Vismodegib—Dyspepsia—Thiotepa—urinary bladder cancer	0.000431	0.00342	CcSEcCtD
Vismodegib—ABCB1—female reproductive system—urinary bladder cancer	0.00043	0.00579	CbGeAlD
Vismodegib—Myalgia—Gemcitabine—urinary bladder cancer	0.00043	0.00341	CcSEcCtD
Vismodegib—Arthralgia—Gemcitabine—urinary bladder cancer	0.00043	0.00341	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.000427	0.00338	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000427	0.00338	CcSEcCtD
Vismodegib—Decreased appetite—Thiotepa—urinary bladder cancer	0.000426	0.00338	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000423	0.00335	CcSEcCtD
Vismodegib—Myalgia—Fluorouracil—urinary bladder cancer	0.000422	0.00335	CcSEcCtD
Vismodegib—Fatigue—Thiotepa—urinary bladder cancer	0.000422	0.00335	CcSEcCtD
Vismodegib—Dysgeusia—Etoposide—urinary bladder cancer	0.000422	0.00335	CcSEcCtD
Vismodegib—Constipation—Thiotepa—urinary bladder cancer	0.000419	0.00332	CcSEcCtD
Vismodegib—Pain—Thiotepa—urinary bladder cancer	0.000419	0.00332	CcSEcCtD
Vismodegib—Back pain—Etoposide—urinary bladder cancer	0.000417	0.00331	CcSEcCtD
Vismodegib—Muscle spasms—Etoposide—urinary bladder cancer	0.000414	0.00329	CcSEcCtD
Vismodegib—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000404	0.0032	CcSEcCtD
Vismodegib—Hyponatraemia—Epirubicin—urinary bladder cancer	0.000403	0.00319	CcSEcCtD
Vismodegib—Pain in extremity—Epirubicin—urinary bladder cancer	0.000401	0.00318	CcSEcCtD
Vismodegib—Myalgia—Cisplatin—urinary bladder cancer	0.0004	0.00318	CcSEcCtD
Vismodegib—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.0004	0.00318	CcSEcCtD
Vismodegib—Skin disorder—Gemcitabine—urinary bladder cancer	0.0004	0.00317	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000398	0.00315	CcSEcCtD
Vismodegib—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000397	0.00315	CcSEcCtD
Vismodegib—ABCB1—vagina—urinary bladder cancer	0.000389	0.00523	CbGeAlD
Vismodegib—Breast disorder—Methotrexate—urinary bladder cancer	0.000387	0.00307	CcSEcCtD
Vismodegib—Abdominal pain—Thiotepa—urinary bladder cancer	0.000387	0.00307	CcSEcCtD
Vismodegib—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000376	0.00299	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000375	0.00298	CcSEcCtD
Vismodegib—Dehydration—Epirubicin—urinary bladder cancer	0.000373	0.00296	CcSEcCtD
Vismodegib—Skin disorder—Cisplatin—urinary bladder cancer	0.000373	0.00296	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000373	0.00296	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000371	0.00294	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000369	0.00293	CcSEcCtD
Vismodegib—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000366	0.00291	CcSEcCtD
Vismodegib—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000365	0.0029	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000364	0.00289	CcSEcCtD
Vismodegib—Breast disorder—Epirubicin—urinary bladder cancer	0.000362	0.00288	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000361	0.00287	CcSEcCtD
Vismodegib—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000358	0.00284	CcSEcCtD
Vismodegib—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000356	0.00283	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000356	0.00282	CcSEcCtD
Vismodegib—Fatigue—Gemcitabine—urinary bladder cancer	0.000355	0.00282	CcSEcCtD
Vismodegib—Pain—Gemcitabine—urinary bladder cancer	0.000352	0.00279	CcSEcCtD
Vismodegib—Constipation—Gemcitabine—urinary bladder cancer	0.000352	0.00279	CcSEcCtD
Vismodegib—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000352	0.00279	CcSEcCtD
Vismodegib—Asthenia—Thiotepa—urinary bladder cancer	0.000351	0.00279	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00035	0.00277	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00035	0.00277	CcSEcCtD
Vismodegib—Pruritus—Thiotepa—urinary bladder cancer	0.000346	0.00275	CcSEcCtD
Vismodegib—Pain—Fluorouracil—urinary bladder cancer	0.000346	0.00275	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—urinary bladder cancer	0.000345	0.00274	CcSEcCtD
Vismodegib—Skin disorder—Etoposide—urinary bladder cancer	0.000342	0.00271	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000339	0.00269	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000338	0.00268	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—urinary bladder cancer	0.000335	0.00266	CcSEcCtD
Vismodegib—Diarrhoea—Thiotepa—urinary bladder cancer	0.000335	0.00266	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000334	0.00265	CcSEcCtD
Vismodegib—Decreased appetite—Cisplatin—urinary bladder cancer	0.000334	0.00265	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000331	0.00263	CcSEcCtD
Vismodegib—Pain—Cisplatin—urinary bladder cancer	0.000328	0.0026	CcSEcCtD
Vismodegib—Weight decreased—Epirubicin—urinary bladder cancer	0.000314	0.00249	CcSEcCtD
Vismodegib—Vomiting—Thiotepa—urinary bladder cancer	0.000311	0.00247	CcSEcCtD
Vismodegib—Rash—Thiotepa—urinary bladder cancer	0.000309	0.00245	CcSEcCtD
Vismodegib—Dermatitis—Thiotepa—urinary bladder cancer	0.000308	0.00245	CcSEcCtD
Vismodegib—Decreased appetite—Etoposide—urinary bladder cancer	0.000306	0.00243	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000304	0.00241	CcSEcCtD
Vismodegib—Fatigue—Etoposide—urinary bladder cancer	0.000303	0.00241	CcSEcCtD
Vismodegib—Pain—Etoposide—urinary bladder cancer	0.000301	0.00239	CcSEcCtD
Vismodegib—Constipation—Etoposide—urinary bladder cancer	0.000301	0.00239	CcSEcCtD
Vismodegib—Asthenia—Gemcitabine—urinary bladder cancer	0.000295	0.00234	CcSEcCtD
Vismodegib—Pruritus—Gemcitabine—urinary bladder cancer	0.000291	0.00231	CcSEcCtD
Vismodegib—Nausea—Thiotepa—urinary bladder cancer	0.000291	0.00231	CcSEcCtD
Vismodegib—Weight decreased—Doxorubicin—urinary bladder cancer	0.00029	0.0023	CcSEcCtD
Vismodegib—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000288	0.00228	CcSEcCtD
Vismodegib—Pruritus—Fluorouracil—urinary bladder cancer	0.000286	0.00227	CcSEcCtD
Vismodegib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000282	0.00224	CcSEcCtD
Vismodegib—Abdominal pain—Etoposide—urinary bladder cancer	0.000278	0.00221	CcSEcCtD
Vismodegib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000277	0.0022	CcSEcCtD
Vismodegib—Asthenia—Cisplatin—urinary bladder cancer	0.000275	0.00218	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000273	0.00216	CcSEcCtD
Vismodegib—Diarrhoea—Cisplatin—urinary bladder cancer	0.000263	0.00208	CcSEcCtD
Vismodegib—Alopecia—Methotrexate—urinary bladder cancer	0.000262	0.00208	CcSEcCtD
Vismodegib—Vomiting—Gemcitabine—urinary bladder cancer	0.000262	0.00208	CcSEcCtD
Vismodegib—Rash—Gemcitabine—urinary bladder cancer	0.00026	0.00206	CcSEcCtD
Vismodegib—Dermatitis—Gemcitabine—urinary bladder cancer	0.000259	0.00206	CcSEcCtD
Vismodegib—Malnutrition—Methotrexate—urinary bladder cancer	0.000258	0.00205	CcSEcCtD
Vismodegib—Vomiting—Fluorouracil—urinary bladder cancer	0.000257	0.00204	CcSEcCtD
Vismodegib—Rash—Fluorouracil—urinary bladder cancer	0.000255	0.00203	CcSEcCtD
Vismodegib—Dermatitis—Fluorouracil—urinary bladder cancer	0.000255	0.00202	CcSEcCtD
Vismodegib—Dysgeusia—Methotrexate—urinary bladder cancer	0.000253	0.00201	CcSEcCtD
Vismodegib—Asthenia—Etoposide—urinary bladder cancer	0.000252	0.002	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000252	0.002	CcSEcCtD
Vismodegib—ABCB1—lymph node—urinary bladder cancer	0.000252	0.00339	CbGeAlD
Vismodegib—Back pain—Methotrexate—urinary bladder cancer	0.00025	0.00198	CcSEcCtD
Vismodegib—Pruritus—Etoposide—urinary bladder cancer	0.000249	0.00197	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—urinary bladder cancer	0.000245	0.00195	CcSEcCtD
Vismodegib—Nausea—Gemcitabine—urinary bladder cancer	0.000245	0.00194	CcSEcCtD
Vismodegib—Vomiting—Cisplatin—urinary bladder cancer	0.000244	0.00194	CcSEcCtD
Vismodegib—Rash—Cisplatin—urinary bladder cancer	0.000242	0.00192	CcSEcCtD
Vismodegib—Dermatitis—Cisplatin—urinary bladder cancer	0.000242	0.00192	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—urinary bladder cancer	0.000242	0.00192	CcSEcCtD
Vismodegib—Diarrhoea—Etoposide—urinary bladder cancer	0.000241	0.00191	CcSEcCtD
Vismodegib—Nausea—Fluorouracil—urinary bladder cancer	0.000241	0.00191	CcSEcCtD
Vismodegib—Dysgeusia—Epirubicin—urinary bladder cancer	0.000237	0.00188	CcSEcCtD
Vismodegib—Back pain—Epirubicin—urinary bladder cancer	0.000234	0.00185	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—urinary bladder cancer	0.000232	0.00184	CcSEcCtD
Vismodegib—Nausea—Cisplatin—urinary bladder cancer	0.000228	0.00181	CcSEcCtD
Vismodegib—Alopecia—Doxorubicin—urinary bladder cancer	0.000227	0.0018	CcSEcCtD
Vismodegib—Vomiting—Etoposide—urinary bladder cancer	0.000224	0.00177	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—urinary bladder cancer	0.000223	0.00177	CcSEcCtD
Vismodegib—Rash—Etoposide—urinary bladder cancer	0.000222	0.00176	CcSEcCtD
Vismodegib—Dermatitis—Etoposide—urinary bladder cancer	0.000222	0.00176	CcSEcCtD
Vismodegib—Myalgia—Methotrexate—urinary bladder cancer	0.00022	0.00174	CcSEcCtD
Vismodegib—Arthralgia—Methotrexate—urinary bladder cancer	0.00022	0.00174	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000219	0.00174	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000218	0.00173	CcSEcCtD
Vismodegib—Back pain—Doxorubicin—urinary bladder cancer	0.000216	0.00171	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000215	0.0017	CcSEcCtD
Vismodegib—Nausea—Etoposide—urinary bladder cancer	0.000209	0.00166	CcSEcCtD
Vismodegib—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000207	0.00164	CcSEcCtD
Vismodegib—Arthralgia—Epirubicin—urinary bladder cancer	0.000206	0.00163	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—urinary bladder cancer	0.000206	0.00163	CcSEcCtD
Vismodegib—Skin disorder—Methotrexate—urinary bladder cancer	0.000205	0.00162	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000204	0.00162	CcSEcCtD
Vismodegib—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000193	0.00153	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000192	0.00152	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—urinary bladder cancer	0.000191	0.00152	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—urinary bladder cancer	0.00019	0.00151	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—urinary bladder cancer	0.00019	0.00151	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000189	0.0015	CcSEcCtD
Vismodegib—Dyspepsia—Methotrexate—urinary bladder cancer	0.000185	0.00147	CcSEcCtD
Vismodegib—Decreased appetite—Methotrexate—urinary bladder cancer	0.000183	0.00145	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000182	0.00144	CcSEcCtD
Vismodegib—Fatigue—Methotrexate—urinary bladder cancer	0.000182	0.00144	CcSEcCtD
Vismodegib—Pain—Methotrexate—urinary bladder cancer	0.00018	0.00143	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00018	0.00142	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000179	0.00142	CcSEcCtD
Vismodegib—Skin disorder—Doxorubicin—urinary bladder cancer	0.000177	0.00141	CcSEcCtD
Vismodegib—Dyspepsia—Epirubicin—urinary bladder cancer	0.000174	0.00138	CcSEcCtD
Vismodegib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000172	0.00137	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—urinary bladder cancer	0.000171	0.00136	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00017	0.00135	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—urinary bladder cancer	0.00017	0.00135	CcSEcCtD
Vismodegib—Constipation—Epirubicin—urinary bladder cancer	0.000169	0.00134	CcSEcCtD
Vismodegib—Pain—Epirubicin—urinary bladder cancer	0.000169	0.00134	CcSEcCtD
Vismodegib—Abdominal pain—Methotrexate—urinary bladder cancer	0.000167	0.00132	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000166	0.00132	CcSEcCtD
Vismodegib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000161	0.00128	CcSEcCtD
Vismodegib—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000161	0.00127	CcSEcCtD
Vismodegib—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000159	0.00126	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000157	0.00125	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—urinary bladder cancer	0.000157	0.00125	CcSEcCtD
Vismodegib—Pain—Doxorubicin—urinary bladder cancer	0.000156	0.00124	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—urinary bladder cancer	0.000156	0.00124	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—urinary bladder cancer	0.000156	0.00124	CcSEcCtD
Vismodegib—Asthenia—Methotrexate—urinary bladder cancer	0.000151	0.0012	CcSEcCtD
Vismodegib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000149	0.00118	CcSEcCtD
Vismodegib—Pruritus—Methotrexate—urinary bladder cancer	0.000149	0.00118	CcSEcCtD
Vismodegib—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000144	0.00114	CcSEcCtD
Vismodegib—Diarrhoea—Methotrexate—urinary bladder cancer	0.000144	0.00114	CcSEcCtD
Vismodegib—Asthenia—Epirubicin—urinary bladder cancer	0.000141	0.00112	CcSEcCtD
Vismodegib—Pruritus—Epirubicin—urinary bladder cancer	0.000139	0.00111	CcSEcCtD
Vismodegib—Diarrhoea—Epirubicin—urinary bladder cancer	0.000135	0.00107	CcSEcCtD
Vismodegib—Vomiting—Methotrexate—urinary bladder cancer	0.000134	0.00106	CcSEcCtD
Vismodegib—Rash—Methotrexate—urinary bladder cancer	0.000133	0.00105	CcSEcCtD
Vismodegib—Dermatitis—Methotrexate—urinary bladder cancer	0.000133	0.00105	CcSEcCtD
Vismodegib—Asthenia—Doxorubicin—urinary bladder cancer	0.000131	0.00104	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—urinary bladder cancer	0.000129	0.00102	CcSEcCtD
Vismodegib—Vomiting—Epirubicin—urinary bladder cancer	0.000125	0.000994	CcSEcCtD
Vismodegib—Nausea—Methotrexate—urinary bladder cancer	0.000125	0.000993	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000125	0.00099	CcSEcCtD
Vismodegib—Rash—Epirubicin—urinary bladder cancer	0.000124	0.000986	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—urinary bladder cancer	0.000124	0.000985	CcSEcCtD
Vismodegib—Nausea—Epirubicin—urinary bladder cancer	0.000117	0.000929	CcSEcCtD
Vismodegib—Vomiting—Doxorubicin—urinary bladder cancer	0.000116	0.00092	CcSEcCtD
Vismodegib—Rash—Doxorubicin—urinary bladder cancer	0.000115	0.000912	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—urinary bladder cancer	0.000115	0.000911	CcSEcCtD
Vismodegib—Nausea—Doxorubicin—urinary bladder cancer	0.000108	0.000859	CcSEcCtD
Vismodegib—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.1e-05	0.000285	CbGpPWpGaD
Vismodegib—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.07e-05	0.000283	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CXCL8—urinary bladder cancer	4.07e-05	0.000283	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—ERBB2—urinary bladder cancer	4.07e-05	0.000283	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—HRAS—urinary bladder cancer	4.04e-05	0.000281	CbGpPWpGaD
Vismodegib—SHH—Disease—KRAS—urinary bladder cancer	4.01e-05	0.000279	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	4e-05	0.000278	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP4B1—urinary bladder cancer	3.98e-05	0.000276	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	3.97e-05	0.000276	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NAT1—urinary bladder cancer	3.95e-05	0.000275	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	3.95e-05	0.000275	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	3.89e-05	0.000271	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL2—urinary bladder cancer	3.89e-05	0.00027	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.89e-05	0.00027	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	3.87e-05	0.000269	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CXCL8—urinary bladder cancer	3.86e-05	0.000268	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—HRAS—urinary bladder cancer	3.83e-05	0.000266	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IFNA2—urinary bladder cancer	3.79e-05	0.000264	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCND1—urinary bladder cancer	3.79e-05	0.000264	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	3.78e-05	0.000263	CbGpPWpGaD
Vismodegib—ALB—Metabolism—SLC19A1—urinary bladder cancer	3.76e-05	0.000261	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—RRM2—urinary bladder cancer	3.7e-05	0.000257	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL2—urinary bladder cancer	3.69e-05	0.000256	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	3.68e-05	0.000256	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MMP9—urinary bladder cancer	3.68e-05	0.000256	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CDKN1A—urinary bladder cancer	3.67e-05	0.000255	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PRSS3—urinary bladder cancer	3.66e-05	0.000254	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTEN—urinary bladder cancer	3.66e-05	0.000254	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	3.62e-05	0.000251	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.6e-05	0.00025	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCND1—urinary bladder cancer	3.59e-05	0.00025	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	3.57e-05	0.000248	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.55e-05	0.000247	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—EP300—urinary bladder cancer	3.49e-05	0.000243	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MMP9—urinary bladder cancer	3.49e-05	0.000243	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.48e-05	0.000242	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CDKN1A—urinary bladder cancer	3.48e-05	0.000242	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.47e-05	0.000241	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTEN—urinary bladder cancer	3.47e-05	0.000241	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—HPGDS—urinary bladder cancer	3.43e-05	0.000238	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ENO2—urinary bladder cancer	3.43e-05	0.000238	CbGpPWpGaD
Vismodegib—SHH—Disease—HRAS—urinary bladder cancer	3.41e-05	0.000237	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—SRC—urinary bladder cancer	3.39e-05	0.000236	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	3.37e-05	0.000234	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—GSTT1—urinary bladder cancer	3.33e-05	0.000231	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—EP300—urinary bladder cancer	3.31e-05	0.00023	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	3.29e-05	0.000229	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	3.29e-05	0.000228	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	3.27e-05	0.000227	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	3.26e-05	0.000226	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SRC—urinary bladder cancer	3.22e-05	0.000224	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PRSS3—urinary bladder cancer	3.21e-05	0.000223	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.14e-05	0.000218	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.11e-05	0.000216	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.07e-05	0.000214	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MYC—urinary bladder cancer	3.04e-05	0.000211	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.03e-05	0.000211	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.03e-05	0.00021	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3e-05	0.000208	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—EGFR—urinary bladder cancer	2.97e-05	0.000207	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.95e-05	0.000205	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—TYMP—urinary bladder cancer	2.94e-05	0.000205	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.93e-05	0.000204	CbGpPWpGaD
Vismodegib—ALB—Metabolism—TYMP—urinary bladder cancer	2.93e-05	0.000203	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.89e-05	0.000201	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MYC—urinary bladder cancer	2.88e-05	0.0002	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.85e-05	0.000198	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.83e-05	0.000196	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—EGFR—urinary bladder cancer	2.82e-05	0.000196	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.81e-05	0.000195	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KRAS—urinary bladder cancer	2.81e-05	0.000195	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.81e-05	0.000195	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—NQO1—urinary bladder cancer	2.76e-05	0.000192	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.75e-05	0.000191	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PLAU—urinary bladder cancer	2.69e-05	0.000187	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KRAS—urinary bladder cancer	2.66e-05	0.000185	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.66e-05	0.000185	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NAT2—urinary bladder cancer	2.65e-05	0.000184	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.63e-05	0.000183	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TYMP—urinary bladder cancer	2.63e-05	0.000183	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.61e-05	0.000181	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.61e-05	0.000181	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.56e-05	0.000178	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.52e-05	0.000175	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.52e-05	0.000175	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—urinary bladder cancer	2.5e-05	0.000174	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.46e-05	0.000171	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.4e-05	0.000167	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.39e-05	0.000166	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HRAS—urinary bladder cancer	2.39e-05	0.000166	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.38e-05	0.000166	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.38e-05	0.000165	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—urinary bladder cancer	2.37e-05	0.000165	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.34e-05	0.000163	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.32e-05	0.000162	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.32e-05	0.000161	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—GSTP1—urinary bladder cancer	2.3e-05	0.00016	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.3e-05	0.00016	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—RRM2—urinary bladder cancer	2.3e-05	0.00016	CbGpPWpGaD
Vismodegib—ALB—Metabolism—RRM2—urinary bladder cancer	2.28e-05	0.000159	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HRAS—urinary bladder cancer	2.26e-05	0.000157	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—CREBBP—urinary bladder cancer	2.22e-05	0.000154	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IGF1—urinary bladder cancer	2.19e-05	0.000152	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.17e-05	0.000151	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.15e-05	0.000149	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—TYMS—urinary bladder cancer	2.14e-05	0.000149	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	2.13e-05	0.000148	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ENO2—urinary bladder cancer	2.13e-05	0.000148	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—GSTM1—urinary bladder cancer	2.12e-05	0.000147	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—NCOR1—urinary bladder cancer	2.12e-05	0.000147	CbGpPWpGaD
Vismodegib—ALB—Metabolism—HPGDS—urinary bladder cancer	2.12e-05	0.000147	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ENO2—urinary bladder cancer	2.12e-05	0.000147	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.12e-05	0.000147	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.1e-05	0.000146	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.07e-05	0.000144	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.06e-05	0.000143	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GSTT1—urinary bladder cancer	2.05e-05	0.000143	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.05e-05	0.000143	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.03e-05	0.000141	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—GPX1—urinary bladder cancer	2.03e-05	0.000141	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.03e-05	0.000141	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.02e-05	0.00014	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—RHOA—urinary bladder cancer	2.01e-05	0.00014	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—RRM2—urinary bladder cancer	2e-05	0.000139	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ERCC2—urinary bladder cancer	1.99e-05	0.000138	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.98e-05	0.000137	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.92e-05	0.000134	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.9e-05	0.000132	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.9e-05	0.000132	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.89e-05	0.000131	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—MTHFR—urinary bladder cancer	1.87e-05	0.00013	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.87e-05	0.00013	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.85e-05	0.000129	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.85e-05	0.000129	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.84e-05	0.000128	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.81e-05	0.000126	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.8e-05	0.000125	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.73e-05	0.00012	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.73e-05	0.00012	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.72e-05	0.00012	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.71e-05	0.000119	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NQO1—urinary bladder cancer	1.71e-05	0.000119	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IL2—urinary bladder cancer	1.68e-05	0.000117	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.68e-05	0.000117	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.68e-05	0.000117	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.66e-05	0.000116	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.65e-05	0.000115	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.65e-05	0.000115	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.58e-05	0.00011	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.53e-05	0.000106	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.52e-05	0.000106	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—EP300—urinary bladder cancer	1.51e-05	0.000105	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.49e-05	0.000104	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.49e-05	0.000103	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—SRC—urinary bladder cancer	1.47e-05	0.000102	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.46e-05	0.000101	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.45e-05	0.000101	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.44e-05	0.0001	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.43e-05	9.94e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.43e-05	9.93e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GSTP1—urinary bladder cancer	1.42e-05	9.89e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.4e-05	9.7e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.38e-05	9.62e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.38e-05	9.57e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.35e-05	9.41e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.33e-05	9.24e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—TYMS—urinary bladder cancer	1.32e-05	9.19e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.31e-05	9.14e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.31e-05	9.14e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GSTM1—urinary bladder cancer	1.31e-05	9.09e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NCOR1—urinary bladder cancer	1.31e-05	9.09e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.3e-05	9e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.28e-05	8.88e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.26e-05	8.75e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GPX1—urinary bladder cancer	1.25e-05	8.7e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	8.66e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.24e-05	8.59e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.24e-05	8.59e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.23e-05	8.57e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ERCC2—urinary bladder cancer	1.23e-05	8.54e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—urinary bladder cancer	1.22e-05	8.46e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.19e-05	8.3e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.19e-05	8.25e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.18e-05	8.21e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.17e-05	8.16e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.17e-05	8.16e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.16e-05	8.09e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.16e-05	8.08e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.16e-05	8.05e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—MTHFR—urinary bladder cancer	1.16e-05	8.03e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	7.96e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	7.96e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.14e-05	7.94e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.14e-05	7.94e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.13e-05	7.83e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.12e-05	7.81e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.11e-05	7.7e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.1e-05	7.67e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.1e-05	7.62e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.08e-05	7.52e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—urinary bladder cancer	1.08e-05	7.52e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	7.48e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.07e-05	7.44e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.07e-05	7.44e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.04e-05	7.24e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.04e-05	7.21e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—urinary bladder cancer	1.03e-05	7.19e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.02e-05	7.12e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.01e-05	7.04e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.01e-05	6.99e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—EP300—urinary bladder cancer	9.93e-06	6.9e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	9.45e-06	6.57e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PPARG—urinary bladder cancer	9.42e-06	6.55e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PPARG—urinary bladder cancer	9.37e-06	6.51e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.2e-06	6.4e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	9.05e-06	6.29e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CREBBP—urinary bladder cancer	9e-06	6.25e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PPARG—urinary bladder cancer	8.41e-06	5.84e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.21e-06	5.7e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	8.08e-06	5.61e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.88e-06	5.48e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.68e-06	5.34e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PPARG—urinary bladder cancer	7.67e-06	5.33e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	7.41e-06	5.15e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTGS2—urinary bladder cancer	7.37e-06	5.12e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	7.36e-06	5.12e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.14e-06	4.96e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.05e-06	4.9e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.05e-06	4.9e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.76e-06	4.7e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.63e-06	4.61e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	6.61e-06	4.6e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTEN—urinary bladder cancer	6.46e-06	4.49e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.46e-06	4.49e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTEN—urinary bladder cancer	6.43e-06	4.47e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.23e-06	4.33e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.16e-06	4.28e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—EP300—urinary bladder cancer	6.13e-06	4.26e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	6.03e-06	4.19e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTEN—urinary bladder cancer	5.77e-06	4.01e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.63e-06	3.91e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—EP300—urinary bladder cancer	5.5e-06	3.82e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—EP300—urinary bladder cancer	5.37e-06	3.73e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.26e-06	3.66e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.06e-06	3.51e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.02e-06	3.49e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.86e-06	3.38e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.98e-06	2.76e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.47e-06	2.41e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.31e-06	2.3e-05	CbGpPWpGaD
